Crossmark

Is glycaemic control still central in the hierarchy of priorities in type 2 diabetes management? The way forward is to combine glucose control and the prevention of cardiorenal complications

Crossref DOI link: https://doi.org/10.1007/s00125-024-06284-4

Published Online: 2024-10-04

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ceriello, Antonio

Prattichizzo, Francesco

Berra, Cesare
License Information

Text and Data Mining valid from 2024-10-04

Version of Record valid from 2024-10-04
More Information

Article History

Received: 20 August 2024

Accepted: 28 August 2024

First Online: 4 October 2024

Funding

: Work in the authors’ laboratories is supported by a grant from the Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (Scientific research programs of high national interest), project n 2020LM8WNW to RM and by funding from the Italian Ministry of Health - Ricerca Corrente to IRCCS MultiMedica.

: AC has received fees for consultancy from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Roche Diagnostics, Sanofi and Servier, and served on the speakers’ bureau for Bayer, Berlin-Chemie, Boehringer Ingelheim, Hikamr Pharma, Guidotti, MSD, Merck and SUN Pharma. FP has served on the speakers’ bureau for Berlin-Chemie. CB has served on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk.

: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below